Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormonereceptor-positive metastatic breast cancer

Projekt

Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormonereceptor-positive metastatic breast cancer

Abgeschlossen · 2008 bis 2009

Ruhstaller Thomas, Räss Andrea

Art

Klinische Forschung

Reichweite

Multizentrisch, KSSG als teilnehmendes Zentrum

Bereiche

Brustzentrum St.Gallen, Endokrinologie | Diabetologie | Osteologie | Stoffwechselerkrankungen

Status

Abgeschlossen

Start

2008

Ende

2009

Finanzierungsart

Industrie

Studiendesign

Prospective, randomized, open-label, parallel group, multi-center

Schlagwörter (Tags)

hormone receptor-positive tumors, breast cancer

Projektpartner

Prof. Walter Jonat, Kiel, Klinik für Gynäkologie und Geburtshilfe Dr. Iris Kuss Bayer Schering Pharma AG, Study Team Lead, Dr. Michael, Bayer Schering Pharma AG, Dr. Kretschmann Bayer Schering Pharma AG

Kurzbeschreibung/Zielsetzung

Breast cancer is the second leading cause of cancer-related death in women today (after lung cancer) and is the most common cancer among women worldwide. According to the World Health Organization (WHO), more than 1.2 million people will be diagnosed with breast cancer worldwide in 2005 (Imaginis 2005).
The risk of developing breast cancer increases with age with about two thirds of breast cancers occurring in postmenopausal women. Endocrine therapy is the most important systemic treatment for patients with hormone receptor-positive tumors, which account for two thirds of
breast cancers.